Low Protein Diet, Gut Microbiome and Chronic Kidney Disease

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05019599
Collaborator
Ministry of Science and Technology, Taiwan (Other)
100
1
3
27
3.7

Study Details

Study Description

Brief Summary

Chronic kidney disease (CKD) is a worldwide public health dilemma because of close association with multiple comorbidities, demanding high cardiovascular events, mortality and expensive medical cost. Novel and effective therapeutic measures remain urgently needed to reduce burden and impact of disease. Advanced renal failure can profoundly alter the biochemical milieu of the gastrointestinal tract leading to a leak gut. Application of 16s rRNA gene analysis identified an increase of Clostridia, Actinobacteria, and Gammaproteobacteria in hemodialysis patients and decrease of Bifidobacterium and lactobacillus in peritoneal patients. This altered microbiome consequently affect production of indole or phenol derived uremic toxins leading to renal damage. Our preliminary results indicated reduced number and diversity of intestinal microbes CKD patients compared to normal. Different dietary nutrients can affect the gut microbiome and derive several deleterious metabolites leading to metabolic disarrangement. Clinically, low-protein diet should be prescribe to renal patients to preserve renal function and high fat content are usually recommended to avoid caloric malnutrition to dietary restriction. The changes of diet-microbiome-metabolite interaction are large unknown with this dietary manipulation. The aims of this study is to determine the renal progression-associated gene and taxonomic alterations bymetagenome-wide association studies and the functional characterization of gut microbiome in CKD patients receiving different low-protein or high-fat diets. The results of the study will provide insight on the exact role of dietary manipulation in CKD patients from gut-renal cross talk.

Condition or Disease Intervention/Treatment Phase
  • Other: low protein diet
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
nutritional intervention with low protein diet (< 0.8 G protein/kg body weight/day)nutritional intervention with low protein diet (< 0.8 G protein/kg body weight/day)
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Exploring the Role of Low Protein Diet on the Gut Microbiome, Related Metabolites and Renal Function in Chronic Kidney Disease
Actual Study Start Date :
Aug 1, 2019
Actual Primary Completion Date :
Jul 31, 2020
Anticipated Study Completion Date :
Oct 31, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: normal controls

subjects with normal renal function

Experimental: CKD_Low protein diet

CKD patient with low protein diet (<0.8g/kg/BW)

Other: low protein diet
Low protein diet (<0.8g/kg/BW/day)

Active Comparator: CKD_normal protein diet

CKD patient with normal protein diet

Other: low protein diet
Low protein diet (<0.8g/kg/BW/day)

Outcome Measures

Primary Outcome Measures

  1. change of gut microbiota [3 months]

    change of relative abundance of microbes

  2. change of host metabolite concentration [3 months]

    change of concentration of serum metabolomic profile

  3. change of renal function [3 months]

    serum creatinine, estimated glomerular filtration rate or urine total protein

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. . Patients aged 30-90 years with diagnosis of CKD (defined as abovementioned).

  2. . Sign the inform consent and agree to participate in this study.

  3. . Compliant to low protein diet (defined as protein intake <0.8 g/Kg/day) for 4 weeks assessed by 24h urine urea estimates, before enrollment

Exclusion Criteria:
  1. . History of any malignancy, liver cirrhosis, intestinal operation, irritable bowel syndrome, cardiovascular disease (defined as myocardial infarction, documented Q wave on EKG, unstable angina, coronary artery disease with stenosis > 75%, congestive heart failure with Ejection Fraction < 50% and cerebrovascular disease) in the past 3 months.

  2. . History of or infection disease requiring admission in the past 3 months or, concomitant antibiotics use.

  3. . Concomitant use of probiotics or prebiotics.

  4. . Pregnancy.

  5. . Renal transplant recipients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chang Gung Memorial Hospital Keelung Taiwan 204

Sponsors and Collaborators

  • Chang Gung Memorial Hospital
  • Ministry of Science and Technology, Taiwan

Investigators

  • Principal Investigator: I Wen Wu, Chang Gung Memorial Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT05019599
Other Study ID Numbers:
  • IWW-0008
First Posted:
Aug 25, 2021
Last Update Posted:
Aug 25, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2021